$100M stock pop as TH-302 approaches Threshold of success in pancreatic cancer
This article was originally published in Scrip
Threshold Pharmaceutical's hypoxia-targeted drug candidate TH-302 has produced a significant 63% extension in progression-free survival in a Phase IIb study in pancreatic cancer, top-line data show. The drug was the subject of a licensing deal worth up to $525 million with Merck KGaA earlier this month (scripintelligence.com, 3 February 2012), and the share price of Threshold jumped by $2.95 to $6.45 (84%) on the news, before drifting to $5.14 by the end of 21 February 2012. The market thus valued the news of clinical success at around $100 million.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.